Results 31 to 40 of about 2,763 (183)

Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study

BMC Neurology, 2021
Background Erenumab is a calcitonin gene-related peptide (CGRP)-receptor antibody inhibiting CGRP function. CGRP is prominently involved in the pathophysiology of migraine through nociceptive modulation in the trigeminovascular system. This study aims to
Bui Bao Khanh Dinh, Waseem Hamed Aziz, Alessandro Terruzzi, Derk Wolfgang Krieger   +3 more
doaj   +1 more source

Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study

The Journal of Headache and Pain, 2022
Objective HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy of erenumab with topiramate in patients who
Marc Ehrlich, Christian Hentschke, Christian Sieder, Monika Maier-Peuschel, Uwe Reuter   +4 more
doaj   +1 more source

Early use of erenumab in US real-world practice

Cephalalgia Reports, 2021
Background: Erenumab, a monoclonal antibody (mAb) developed to block the calcitonin gene-related peptide (CGRP) receptor, is approved for the prevention of migraine in adults. This retrospective observational study sought to describe early real-world use
Alina Bogdanov, Victoria Chia, Mark Bensink, Robert Urman, Lauren Fischer, Soeren Rasmussen, Christine Szekely, Lee Kallenbach   +7 more
doaj   +1 more source

A Controlled Trial of Erenumab for Episodic Migraine [PDF]

, 2017
BACKGROUND We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene–related peptide receptor, for the prevention of episodic migraine.
Daniel D. Mikol, Mikol, Daniel D., Jo H. Bonner, Broessner, Gregor, Hernan Picard, Sapra, Sandhya, Peter J. Goadsby, Bonner, Jo H., Lenz, Robert A., Yngve Hallström, Sandhya Sapra, Picard, Hernan, Feng Zhang, Reuter, Uwe, Hallström, Yngve, Gregor Broessner, Robert A. Lenz, Goadsby, Peter J.; id_orcid, Uwe Reuter, Zhang, Feng   +19 more
core   +1 more source

Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache [PDF]

, 2021
Objective: To determine whether erenumab is effective and safe in refractory chronic migraine with medication overuse headache. Methods: In this prospective, multicentric, real-life study, chronic migraine with medication overuse headache patients who ...
Quintana S., Querzani P., Cainazzo M. M., Matteo E., Favoni V., Asioli G. M., Cevoli S., Pascazio A., Pensato U., Torelli P., Pierangeli G., Baraldi C., Guerzoni S., Mascarella D., Cortelli P.   +14 more
core   +1 more source

Comparative Clinical Efficacy Study between Erenumab and Fremanezumab [PDF]

, 2022
A retrospective comparative study was conducted to compare the efficacy of monoclonal antibody drugs against the calcitonin gene-related peptide pathway in migraine and to establish whether they can be considered equivalent therapeutic alternatives for ...
Salvador Gómez, Tránsito, Maria de los Ángeles Allende, Merchán Flores, Aritz, Arenere Mendoza, Mercedes, Jose Manuel Vinuesa, Raquel Fresquet, Sopena Carrera, Lucía, Maria Perez, Frutos Pérez-Surio, Alberto, Cazorla Poderoso, Lucía, Lucía Cazorla, Tránsito Salvador, Allende Bandrés, María de los Ángeles, Aritz Merchan, Vinuesa Hernando, José Manuel, Maria del Puerto Pardo, Alberto Frutos, Pérez Moreno, María, Lucia Sopena, Fresquet Molina, Raquel, Mercedes Arenere, Pardo Jario, María del Puerto   +21 more
core   +1 more source

Identification of predictors of response to Erenumab in a cohort of patients with migraine

Cephalalgia Reports, 2021
Background: The migraine-specific monoclonal antibody Erenumab targeting the calcitonin gene related peptide receptor is an effective and well tolerated preventive treatment of episodic and chronic migraine.
Houssein Salem-Abdou, David Simonyan, Jack Puymirat   +2 more
doaj   +1 more source

Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report

BMC Neurology, 2021
Background Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, is registered for migraine prevention. Compared to other conventional migraine prevention medicines (i.e.
C. K. Cullum, M. K. Olsen, H. B. Kocadag, M. Ashina, F. M. Amin   +4 more
doaj   +1 more source

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

Frontiers in Neurology, 2020
Background: German authorities reimburse migraine prevention with erenumab only in patients who previously did not have therapeutic success with at least five oral prophylactics or have contraindications to such.
Bianca Raffaelli, Bianca Raffaelli, Rea Kalantzis, Jasper Mecklenburg, Lucas Hendrik Overeem, Lars Neeb, Astrid Gendolla, Uwe Reuter   +7 more
doaj   +1 more source

Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany

The Journal of Headache and Pain, 2021
Background Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in randomized clinical trials. Large-
Andreas Straube, Philipp Stude, Charly Gaul, Katrin Schuh, Mirja Koch   +4 more
doaj   +1 more source